Department of Pharmacy, Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana.
University of Arizona College of Medicine-Phoenix, Phoenix, Arizona.
Pharmacotherapy. 2017 Nov;37(11):1341-1346. doi: 10.1002/phar.2019. Epub 2017 Sep 28.
To determine the optimal vancomycin dosing regimen to achieve empirical goal trough concentrations in pediatric patients with congenital heart disease and to examine the impact of cardiopulmonary bypass on vancomycin dosing requirements.
Patients younger than 18 years admitted to the pediatric cardiovascular intensive care unit (CVICU) at our institution from October 1, 2012-December 31, 2014, who received at least one dose of vancomycin, were reviewed retrospectively. Included patients had a steady-state vancomycin trough concentration drawn during the study period. The first steady-state vancomycin trough drawn after being initiated on empirical vancomycin therapy was analyzed for each patient. Excluded patients were those who received mechanical circulatory support, any form of renal replacement therapy, or had a serum creatinine result greater than 1.0 mg/dl on the day of vancomycin initiation.
Overall, 77 patients met inclusion criteria, of which 57.1% had undergone cardiopulmonary bypass (CPB) before CVICU admission. Median age was 62 days (interquartile range [IQR] 8.3-176 days). Median daily vancomycin dose was 36.25 mg/kg/day (IQR 29-40 mg/kg/day), resulting in a median steady-state trough of 10.0 μg/ml (IQR 6.3-12.9 μg/ml). Therapeutic troughs occurred in 50.6% of patients; supratherapeutic and subtherapeutic concentrations were attained in 18.2% and 31.2% of patients, respectively. A subgroup analysis of patients who were post-CPB revealed that the only additional variable to affect vancomycin trough concentrations was aortic cross-clamp time (median 56 min, IQR 0-123.3 min, p=0.02).
Empirical vancomycin dosing to achieve troughs of 8-15 μg/dl in patients with congenital heart disease without evidence of significant acute kidney injury should be 30 mg/kg/day for neonates, 35-40 mg/kg/day for infants, and 45 mg/kg/day in children, with adjustments required for patients with elevated creatinine or significant aortic cross-clamp time. The receipt and duration of CPB did not affect total daily vancomycin dose requirements.
确定治疗先天性心脏病患儿经验性目标谷浓度的最佳万古霉素给药方案,并探讨体外循环对万古霉素给药需求的影响。
回顾性分析 2012 年 10 月 1 日至 2014 年 12 月 31 日期间在我院儿科心血管重症监护病房(CVICU)住院且至少接受过一次万古霉素治疗的年龄小于 18 岁的患儿。纳入研究的患儿在研究期间均抽取了稳态万古霉素谷浓度。分析每位患者开始经验性万古霉素治疗后首次抽取的稳态万古霉素谷浓度。排除标准为:接受机械循环支持、任何形式的肾脏替代治疗或万古霉素起始日血清肌酐大于 1.0mg/dl 的患儿。
共有 77 例患儿符合纳入标准,其中 57.1%的患儿在入 CVICU 前接受过体外循环(CPB)。中位年龄为 62 天(四分位间距[IQR]8.3-176 天)。中位日万古霉素剂量为 36.25mg/kg/d(IQR 29-40mg/kg/d),稳态谷浓度中位数为 10.0μg/ml(IQR 6.3-12.9μg/ml)。50.6%的患儿谷浓度达到治疗范围;18.2%和 31.2%的患儿分别达到了超治疗范围和低治疗范围。CPB 后患儿亚组分析表明,唯一影响万古霉素谷浓度的额外变量是主动脉阻断时间(中位数 56 分钟,IQR 0-123.3 分钟,p=0.02)。
对于无明显急性肾损伤的先天性心脏病患儿,经验性万古霉素治疗以达到 8-15μg/dl 的谷浓度时,新生儿的剂量应为 30mg/kg/d,婴儿为 35-40mg/kg/d,儿童为 45mg/kg/d,对于肌酐升高或主动脉阻断时间较长的患者,需要调整剂量。CPB 的实施和持续时间不影响万古霉素的日总剂量需求。